drugset / Trial / NCT05016518

Comparison of Quality of Recovery (QoR)-15 Scores Between Propofol and Remimazolam Anesthesia

NCT05016518

Completed 140 enrolled Gangnam Severance Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Remimazolam is a ultra-short-acting benzodiazepine that is rapidly metabolized in the body by tissue esterase and not accumulates in the body for long periods of infusion. In addition, similar to other benzodiazepines, it is possible to reverse the sedation and anesthetic effects through flumazenil. It has no injection pain and infusion syndrome compared with propofol. There is no study to investigate overall postoperative functional recovery via QoR-15 in patients receiving TIVA using remimazolam. The purpose of this study is to determine whether there is any difference in the quality of postoperative recovery between propofol-based and remimazolam-based total intravenous anesthesia in female patients undergoing thyroidectomy. The QoR-15 questionnaire score, pain, nausea/vomiting, and the frequency of complications are evaluated and compared between the two groups.

Timeline

Start
2021-09-16
Primary completion
2022-05-18
Completion
2022-05-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Propofol Small molecule Intravenous
Comparator Remimazolam Small molecule Intravenous
Background Remifentanil Small molecule Intravenous

Indications